164 related articles for article (PubMed ID: 22878691)
1. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
[No Abstract] [Full Text] [Related]
2. Intravenous voriconazole after toxic oral administration.
Alffenaar JW; van Assen S; de Monchy JG; Uges DR; Kosterink JG; van der Werf TS
Antimicrob Agents Chemother; 2010 Jun; 54(6):2741-2. PubMed ID: 20385853
[TBL] [Abstract][Full Text] [Related]
3. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
Frechen S; Junge L; Saari TI; Suleiman AA; Rokitta D; Neuvonen PJ; Olkkola KT; Fuhr U
Clin Pharmacokinet; 2013 Sep; 52(9):763-81. PubMed ID: 23653047
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
6. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.
Mori T; Kato J; Yamane A; Sakurai M; Kohashi S; Kikuchi T; Ono Y; Okamoto S
Int J Hematol; 2012 May; 95(5):564-9. PubMed ID: 22461034
[TBL] [Abstract][Full Text] [Related]
7. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.
Capone D; Tarantino G; Gentile A; Sabbatini M; Polichetti G; Santangelo M; Nappi R; Ciotola A; D'Alessandro V; Renda A; Basile V; Federico S
J Clin Pharm Ther; 2010 Feb; 35(1):121-4. PubMed ID: 20175821
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole-associated severe hyponatremia.
Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens.
Burhenne J; Haefeli WE; Hess M; Scope A
J Avian Med Surg; 2008 Sep; 22(3):199-207. PubMed ID: 19014092
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole.
Zhao W; Fakhoury M; Maisin A; Baudouin V; Storme T; Deschênes G; Jacqz-Aigrain E
Ther Drug Monit; 2012 Dec; 34(6):739-41. PubMed ID: 23042259
[TBL] [Abstract][Full Text] [Related]
11. Twice-Weekly Tacrolimus Can Overcome Pharmacologic Interaction and Help in the Successful Treatment of Pulmonary Aspergillosis in a Liver Transplant Recipient.
Chiu YC; Ho MH; Chen TW; Hsieh CB; Fan HL
Exp Clin Transplant; 2019 Dec; 17(6):838-840. PubMed ID: 30373507
[TBL] [Abstract][Full Text] [Related]
12. Highly activated oral bioavailability of tacrolimus on coadministration of oral voriconazole.
Inoue Y; Saito T; Takimoto M; Ogawa K; Shibuya Y; Suzuki Y; Kato M; Takahashi M; Miura I; Hatta Y; Takeuchi J
Int J Clin Pharmacol Ther; 2011 Apr; 49(4):291-2. PubMed ID: 21429444
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.
Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P
Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of voriconazole in falcons.
Schmidt V; Demiraj F; Di Somma A; Bailey T; Ungemach FR; Krautwald-Junghanns ME
Vet Rec; 2007 Aug; 161(8):265-8. PubMed ID: 17720963
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.
Peng LW; Lien YH
Am J Kidney Dis; 2005 Jan; 45(1):162-6. PubMed ID: 15696456
[TBL] [Abstract][Full Text] [Related]
16. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.
Mohammedi I; Piens MA; Padoin C; Robert D
Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
[No Abstract] [Full Text] [Related]
19. Safety of voriconazole and dose individualization.
Lutsar I; Hodges MR; Tomaszewski K; Troke PF; Wood ND
Clin Infect Dis; 2003 Apr; 36(8):1087-8. PubMed ID: 12684928
[No Abstract] [Full Text] [Related]
20. An alternative approach to determine oral bioavailability of drugs that follow Michaelis-Menten elimination: a case study with voriconazole.
Verlindo de Araujo B; Farias da Silva C; Costa TD
Pharmacology; 2010; 86(3):163-7. PubMed ID: 20714206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
